AIIMS Delays Treatment for 3-Year-Old Anika, High Court Demands Action
Three-year-old Anika, suffering from the rare disease SMA Type 2, faces a critical delay in her life-saving treatment due to alleged negligence by AIIMS (All India Institute of Medical Sciences). The cost of her treatment is approximately 9.5 crore rupees. So far, 7.5 crore rupees have been raised through crowdfunding and government assistance. However, the procurement of the essential medication is stalled because the necessary invoice has not been received from AIIMS. The Delhi High Court has expressed strong displeasure over the delay and has scheduled the next hearing for July 27th. The family's hope for Anika's recovery hinges on the swift resolution of this bureaucratic hurdle.
The situation highlights a critical intersection of medical necessity, financial resource mobilization, and institutional administrative processes. While public and private efforts have successfully gathered significant funds for Anika's treatment, the delay underscores potential systemic inefficiencies within large healthcare institutions like AIIMS. The high court's intervention signals a need for greater accountability and streamlined processes to ensure timely access to critical care, especially when substantial resources have already been allocated. This case prompts consideration of how to better integrate emergency medical needs with administrative protocols, ensuring that bureaucratic steps do not impede life-saving interventions, particularly in the context of rare diseases where time is of the essence.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.